TME‐Activated Nanofactory Orchestrate NIR‐II Fluorescence/Photoacoustic Imaging‐Guided Synergistic Chemodynamic/Photothermal Antitumor Therapy
Macromolecular Rapid Communications · 19.09.2026
DOI: 10.1002/marc.70434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Rapid Communications, online erschienen am 19.09.2026. Verfasst von Rong Dai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Key Laboratory of Optical-Spectral Imaging Technology and Equipment, Laboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical Univers…. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Key Laboratory of Nano-imaging and Drug-loaded Preparation of Shanxi Province.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) is a highly aggressive and lethal malignancy with poor response to conventional therapeutic regimens. Thus, there is an urgent need to develop precision theranostic nanoplatforms that integrate accurate imaging guidance with synergistic therapeutic modalities. Herein, a novel responsive multifunctional Ag 2 S/MnO 2 @SiO 2 (AMS) nanofactory was constructed for NIR‐II fluorescence/photoacoustic (NIR‐II FL/PA) imaging‐guided synergistic chemodynamic/photothermal therapy (CDT/PTT) of TNBC. Leveraging the unique biochemical cues of the TME, AMS undergoes efficient degradation, leading to the rapid release of Ag 2 S and Mn 2+ ions. The released Ag 2 S enables precise tumor localization via NIR‐II FL/PA imaging, while simultaneously mediating efficient PTT upon 808 nm laser irradiation. Meanwhile, Mn 2+ ions exhibit Fenton‐like catalytic activity to convert endogenous H 2 O 2 into highly toxic • OH for CDT, and the hyperthermia induced by PTT further accelerates the Fenton‐like reaction to boost CDT efficacy, thus achieving highly efficient synergistic antitumor therapy. Collectively, the AMS nanofactory with favorable biocompatibility provides a promising strategy for precision theranostics of TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanxi Key Laboratory of Optical-Spectral Imaging Technology and Equipment, Laboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, China.
ORCID-Profile: Ziliang Zheng
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Key Laboratory of Nano-imaging and Drug-loaded Preparation of Shanxi Province
- Central Guiding Local Science and Technology Development Fund Projects
- China Postdoctoral Science Foundation
- Shanxi Province Science Foundation General Program
- Shanxi Province Science Foundation for Youths
- Open Fund from Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education
Zitieren
APA
Dai, R., Jiang, C., Liu, H., Li, J., Jin, Y., Zhang, R., & Zheng, Z. (2026). TME‐Activated Nanofactory Orchestrate NIR‐II Fluorescence/Photoacoustic Imaging‐Guided Synergistic Chemodynamic/Photothermal Antitumor Therapy. Macromolecular Rapid Communications. https://doi.org/10.1002/marc.70434
Vancouver
Dai R, Jiang C, Liu H, Li J, Jin Y, Zhang R, et al. TME‐Activated Nanofactory Orchestrate NIR‐II Fluorescence/Photoacoustic Imaging‐Guided Synergistic Chemodynamic/Photothermal Antitumor Therapy. Macromolecular Rapid Communications. 2026. doi:10.1002/marc.70434
BibTeX
@article{Dai2026,
author = {Dai, Rong and Jiang, Chunmei and Liu, Haoyu and Li, Jinxuan and Jin, Yarong and Zhang, Ruiping and Zheng, Ziliang},
title = {TME‐Activated Nanofactory Orchestrate NIR‐II Fluorescence/Photoacoustic Imaging‐Guided Synergistic Chemodynamic/Photothermal Antitumor Therapy},
journal = {Macromolecular Rapid Communications},
year = {2026},
doi = {10.1002/marc.70434}
}
EUVIMED